Arcutis' CEO, Frank Watanabe, commends Todd Tucker's promotion to CHRO, praising his leadership in people-centered programs. Tucker's leadership is expected to boost the company's growth and workforce productivity.
$Arcutis Biotherapeutics(ARQT.US)$Ive posted lots of great news here! Especially since early/mid December! And with the exception of a few, the chat is dead! Which is kinda surprising considering the massive increase in price overall from my December 15/17 post! Is it because so many are enjoying the slow but super untrend and dont want to bring attention to the massive gains! Hehehe. Or did not many actually join in? Hehehe! Just thinking outloud!
1
4
举报
JuliaBiswas :
Not all posts are visible in the chat. Unfortunately.
JuliaBiswas :
I don’t know why. I am following your posts. Just like your biotech related thoughts. Unfortunately not all posts are visible. Sometimes they can be seen only when comments appear under them.
Despite strong revenue growth, the company's P/S ratio remains stagnant, possibly due to waning performance expectations. Its shares have risen, aligning the P/S with industry median. However, its subdued growth projections compared to the industry make its current P/S ratio surprising. Predicted revenues may not sustain positive sentiment, risking shareholders' investments and potential investors paying a premium.
Since the beginning of this year,$英伟达(NVDA.US)$has been leading a group of semiconductor and AI stocks to further rise in response to the breakthroughs in AI technology and a booming industry outlook. However, an increasing number of investors have started to fret over the potential risks behind the high valuations of AI stocks and are scouting for alternative investment opportunities. Some of them have shifted their focus to biotech stocks...
Trytosaveabit楼主Kyle Conroy:
Well a shelf is good and bad! They have the shares registered to use. And if you look at when they used them the price drops a bit! But the good news is they are using the money for operations going forward! So they don’t have to take on new debt! Which is always good when a company don’t have to borrow money! GL
Trytosaveabit楼主Kyle Conroy:
If you’re asking how do we know when they are going to use some of the shares from the shelf? They have to issue a filing with the amount of shares issued and at what price!
$Arcutis Biotherapeutics(ARQT.US)$Arcutis Canada Announces Health Canada Acceptance of the Supplement to a New Drug Submission for Roflumilast Foam 0.3% For Seborrheic Dermatitis in Individuals 9 Years of Age and Older Benzinga· 3 mins ago
Arcutis Biotherapeutics股票讨论区
Hmm?
专栏Don't Just Focus on AI! Biotech Stocks Are Rallying
Update
up a lot, down a lot
News
Benzinga· 3 mins ago
no wonder, they just understand better
no wonder this one has a good rally, $富兰克林生物科技新领域基金(LU0109394709.MF)$ add two million, now public only have 7% left...
most of his stocks run like crazy...
$Harpoon Therapeutics(HARP.US)$$RayzeBio(RYZB.US)$ etc
More reason to study biotech
Now they have a way to treat diabetes, obesity. I believe later they will find a way to cure cancer, Alzheimer and other disease not just treat it and prevent it.
To clone something is unreal before, even travel to mars is real now. ($维珍银河(SPCE.US)$
thank you for wonderful run $Tempest Therapeutics(TPST.US)$$Soleno Therapeutics(SLNO.US)$$Arcutis Biotherapeutics(ARQT.US)$$2seventy bio(TSVT.US)$$Redhill Biopharma(RDHL.US)$ etc... th...
暂无评论